1. Scrip
  2. >>Business
  3. >>Earnings

Novo’s Obesity Franchise On Track For YE22 But Diabetes Pipeline Steals Show During Q3

As Lilly’s Rival Beats Expectations

 
• By Ayisha Sharma

Updates regarding Novo Nordisk’s obesity product Wegovy dominated the Danish firm’s Q3 results call, but observers were also keen to hear of diabetes R&D milestones as Eli Lilly’s competitor Mounjaro entered the market with a bang.  

Nurse making a blood test. . Man's hand with red blood drop with Blood glucose test strip and Glucose meter.
Novo's Traditional Stronghold Has Been In Type 2 Diabetes • Source: Shutterstock

Novo Nordisk A/S’s obesity franchise should be back on track by the end of the year, the firm said during its Q3 earnings, while drawing attention to early- and late-stage developments in its diabetes portfolio which is facing a challenge in the form of Eli Lilly and Company’s Mounjaro (tirzepatide).

The Danish firm’s third-quarter sales rose by 15% at constant exchange rates (CER) to reach DKK 45.57bn ($6.06bn), driven by growing demand for its GLP-1-based diabetes treatments, especially Ozempic (semaglutide injection 0.5mg, 1mg, 2mg). Third quarter sales of the GLP-1 franchise rose by 44% to DKK22

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

More from Business

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, and Lisa Takagi

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.